Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.49 CAD | +2.76% | -1.32% | -16.76% |
May. 24 | Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer | MT |
May. 15 | Transcript : Oncolytics Biotech Inc. - Shareholder/Analyst Call |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.76% | 80.28M | |
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
-22.79% | 18.9B | |
+4.70% | 12.67B | |
+24.10% | 12.27B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- Transcript : Oncolytics Biotech Inc., Q4 2022 Earnings Call, Mar 03, 2023